Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Erythropoietin Levels in Patients with Multiple SclerosisComplicated with Anemia.
RANTES and fibroblast growth factor 2 in jawbone cavitations: triggers for systemic disease?
Neuropathologic, phenotypic and functional analyses of Mucosal Associated Invariant T cells in Multiple Sclerosis.
Exercise training improves depressive symptoms in people with multiple sclerosis: Results of a meta-analysis.
Visual Outcomes in Pediatric Optic Neuritis.
Methods for identifying subject-specific abnormalities in neuroimaging data.
How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?
Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.
LONGITUDINAL INTENSITY NORMALIZATION IN THE PRESENCE OF MULTIPLE SCLEROSIS LESIONS.
Trigeminal neuralgia: a condition to be better understood.
Innate IFN-γ promotes development of experimental autoimmune encephalomyelitis: A role for NK cells and M1 macrophages.
"I knew what was going to happen if I did nothing and so I was going to do something": Faith, hope, and trust in the decisions of Canadians with multiple sclerosis to seek unproven interventions abroad.
Clinical Nurse Specialist - A serious shortfall in numbers.
[Fampridine and multiple sclerosis.]
Effects of Brain-Derived IL-2 Deficiency and the Development of Autoimmunity on Spatial Learning and Fear Conditioning.
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS). (REFINE)
Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study.
Correction: Characterization of Microcirculation in Multiple Sclerosis Lesions by Dynamic Texture Parameter Analysis (DTPA).
Analysis of symptoms, functional impairments, and participation in occupational therapy for individuals with multiple sclerosis.
Clinical variability and female penetrance in X-linked familial FTD/ALS caused by a P506S mutation in UBQLN2.
Efficacy and safety of natalizumab treatment for relapsing-remitting multiple sclerosis: interim results of the tysabri(r) observational programme in the uk.
The stress-buffering effects of hope on changes in adjustment to caregiving in multiple sclerosis.
MicroRNA-150: A potential regulator in pathogens infection and autoimmune diseases.
HDAC1/2-Dependent P0 Expression Maintains Paranodal and Nodal Integrity Independently of Myelin Stability through Interactions with Neurofascins.
Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.

Pages